In each performance period of the Oncology Care Model for which we've received data, we've seen different aspects of care that we can improve upon in the following 6 months, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.
In each performance period of the Oncology Care Model for which we've received data, we've seen different aspects of care that we can improve upon in the following 6 months, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.
Transcript:
Looking ahead, what are the unmet needs for the practice that could be assisted through a change in government policy?
I think the most critical aspect of government policy that can be addressed through alternative payment models is the payment schema supporting the transition from the fee-for-service environment to the value-based payment environment.
How do you use any lessons learned from data analytics to make any pivots or shifts in strategy?
I think in each performance period of the model for which we've received data, we've seen different aspects of care delivery that we can improve and focus on for the following 6 months. In several instances, this has had to do with the populations of patients in the specific types of cancers that we see in our data as opportunities to improve care delivery.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More